The growing complexity of the operating environment urges pharmaceutical innovation. This essay addresses the need for the integration of advanced technologies in the pharmaceutical supply chain. It justifies the value proposition and presents a concrete use case for the integration of deep learning insights to make data-driven decisions. The supply chain has always been a priority for the pharmaceutical industry; research and development recognizes companies' increasing investment in big data strategies, with plans for a CAGR in big data tool adoption. The work presented herein has a preliminary explorative character to recuperate and integrate evidence from partly overlooked practical experience and know-how. The practical relevance of the essay is directed toward practitioners in pharmaceutical production, supply chain management, logistics, and regulatory agencies. The literature has shown a long-term concern for enhanced performance in the pharmaceutical supply chain network. This essay demonstrates the application of deep learning-driven insights to reveal non-evident flow dependencies. The main aim is to present a comprehensive insight into deep learning-driven decision support. The supply chain is portrayed in a holistic manner, seeking end-to-end visibility. Implications for public policy are discussed, such as data equity: many countries are protecting their populations and economic growth by building resilience and efficiency to ensure the capacity to move goods across supply chains. The implementation strategy is covered. The combined reduction of variability, efficiency as matured richness, reliability (on stochastic flows and their understanding through deep learning and data), and system noise (increased dampening through the inclusiveness of all stakeholders) results in increased responsiveness of supply chains for pharmaceutical products. Future work involves the integration of external data, closing the loop between planning and its application in reality.

Artificial intelligence systems have been previously used to predict post-operative complications in small studies and single institutions. Here we developed a robust artificial intelligence model that predicts the risk of having cardiac, pulmonary, thromboembolic, or septic complications after elective, non-cardiac, non-ambulatory surgery. We combined structured and unstructured electronic health record data from 3.5 million surgical encounters from 25 medical centers between 2009 and 2017. Our neural network model predicted postoperative comorbidities 15 to 80 times faster than classical models. As such, our model can be used to assess the risk of having a specific complication postoperatively in a fraction of a second. With our model, we believe clinicians will be able to identify high-risk surgical patients and use their good judgment to mitigate upcoming risks, ultimately improving patient outcomes [1].

This work details how the integration of cloud computing and advanced data engineering can innovate and reshape patient care and digital infrastructure. In the healthcare sector, cloud services offer the necessary support to generate digitally-oriented services and service kits. These services can contain high levels of availability, low levels of latency, and on-demand scaling capabilities, while following the strictest data protection laws and regulations. On the other hand, these services can be combined with data engineering techniques to construct an ecosystem that enhances and adds an optimized data layer on any cloud environment. This ecosystem includes technologies to acquire, process, and manage healthcare data while respecting all regulatory obligations and institutions and can be part of a comprehensive digitalization strategy. The objective is to augment the healthcare services that the industry offers by leveraging healthcare data and AI technologies. Designed services, processes, and technologies can be described either as industry-agnostic services or healthcare-specific services that process and manage electronic healthcare records (EHR). Industry-agnostic services offer a set of tools and methodologies to conduct optimized data experiments. The goal is to exploit any variety, velocity, volume, and veracity of medical data. Healthcare-specific services offer a set of tools and methodologies to connect to any common EHR vendor in a privacy-preserving manner. Participating companies are thus able to hold, share, and make use of healthcare data in real-time. The proposed architecture can be transformative for the healthcare industry, opening up and facilitating experimentation on new and scalable service models. The transition to a more digital health approach would help overcome the limits encountered in traditional settings. Limitations in the availability of healthcare facilities and healthcare professionals have underpinned the increasing share of telemedicine in the care process. However, the record-keeping of the patients that undergo care outside of traditional healthcare facilities is often missing and can severely influence the continuity of treatment. Identifying new methods to implement disease prevention and early intervention processes is crucial to avoid more extensive treatment and to support those on multiple line therapies. For chronic patients, having a service available that monitors the state of health and intervenes when parameters go off the wanted range is crucial. However, the same patients are the most under the influence of the decision of care providers; a second opinion might be given remotely which the patient can access at any time on-demand. To address these different kinds of services, an ecosystem composed of a dictionary's worth data layer is outlined, able to live and operate seamlessly in any cloud environment. This future work's envisioned outcome is the rapid evolution and re-definition of the European healthcare landscape.